| [1] |
Grinfeld J, Nangalia J, Baxter E J, et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med, 2018, 379(15):1416-1430.
DOI
URL
|
| [2] |
Luque Paz D, Kralovics R, Skoda R C. Genetic basis and molecular profiling in myeloproliferative neoplasms[J]. Blood, 2023, 141(16):1909-1921.
DOI
URL
|
| [3] |
Makarik T V, Abdullaev A O, Nikulina E E, et al. Low JAK2 V617F allele burden in ph-negative chronic myeloproliferative neoplasms is associated with additional CALR or MPL gene mutations[J]. Genes(Basel), 2021, 12(4):559.
|
| [4] |
蒋玲琳, 李曼倩, 常银银, 等. 骨髓增殖性肿瘤JAK2基因和CALR基因突变双表达3例并文献复习[J]. 重庆医学, 2023, 52(17):2713-2716.
|
| [5] |
Scott L M, Tong W, Levine R L, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[J]. N Engl J Med, 2007, 356(5):459-468.
DOI
URL
|
| [6] |
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia:2021 update on diagnosis,risk-stratification and management[J]. Am J Hematol, 2020, 95(12):1599-1613.
DOI
URL
|
| [7] |
Nangalia J, Massie C E, Baxter E J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2[J]. N Engl J Med, 2013, 369(25):2391-2405.
DOI
URL
|
| [8] |
Klampfl T, Gisslinger H, Harutyunyan A S, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms[J]. N Engl J Med, 2013, 369(25):2379-2390.
DOI
URL
|
| [9] |
Lasho T L, Finke C M, Tischer A, et al. Mayo CALR mutation type classification guide using alpha helix propensity[J]. Am J Hematol, 2018, 93(5):E128-E129.
|
| [10] |
Haunstrup L M, Ebbesen L H, Hansen M, et al. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation[J]. Exp Hematol, 2018, 68:62-65.
DOI
PMID
|
| [11] |
Thompson E R, Nguyen T, Kankanige Y, et al. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing[J]. Haematologica, 2021, 106(1):313-315.
DOI
PMID
|
| [12] |
Nishimura M, Nagaharu K, Ikejiri M, et al. Acquisition of JAK2 V617F to CALR-mutated clones accelerates disease progression and might enhance growth capacity[J]. Br J Haematol, 2021, 194(5):e89-e92.
|
| [13] |
Perner F, Perner C, Ernst T, et al. Roles of JAK2 in aging,inflammation,hematopoiesis and malignant transformation[J]. Cells, 2019, 8(8):854.
DOI
URL
|
| [14] |
Wang Y, Ran F, Lin J, et al. Genetic and clinical characteristics of patients with philadelphia-negative myeloproliferative neoplasm carrying concurrent mutations in JAK2V617F,CALR,and MPL[J]. Technol Cancer Res Treat, 2023, 22:15330338231154092.
DOI
URL
|
| [15] |
Lim K H, Chang Y C, Gon-shen Chen C, et al. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis[J]. Blood Cancer J, 2015, 5(3):e295.
DOI
|
| [16] |
Schueller C M, Majoros A, Nivarthi H, et al. Co-expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness[J]. Am J Hematol, 2022, 97(11):E396-E399.
|
| [17] |
Tefferi A, Vannucchi A M, Barbui T. Essential thrombocythemia:2024 update on diagnosis,risk stratification,and management[J]. Am J Hematol,2024, 99(4):697-718.
DOI
URL
|
